Ten Doctors on FDA Panel Reviewing Abbott Heart Device Had Financial Ties With Company
Most of the doctors the FDA tapped to advise it on an Abbott medical device had financial ties to the company. The FDA didn’t disclose the payments.
FDA
121 - 140 of 470 Results
-
-
At Stake in Mifepristone Case: Abortion, FDA’s Authority, and Return to 1873 Obscenity Law
The end goal for a conservative Christian group’s mifepristone case before the Supreme Court: a de facto nationwide abortion ban.
By Sarah Varney -
A New $16,000 Postpartum Depression Drug Is Here. How Will Insurers Handle It?
A pill form of an effective drug for postpartum depression hit the market in December, but most insurers do not yet have a policy on when or whether they will pay for it. The hurdles to obtain its predecessor medication have advocates worried.
-
-
Toxic Gas That Sterilizes Medical Devices Prompts Safety Rule Update
The Environmental Protection Agency is tightening regulation of ethylene oxide, a carcinogenic gas used to sterilize medical devices. The agency is trying to balance the interests of the health care industry supply chain with those of communities where the gas creates airborne health risks.
By Andy Miller and Sam Whitehead -
‘Behind the Times’: Washington Tries to Catch Up With AI’s Use in Health Care
Lawmakers and regulators are trying to understand how AI is changing health care and how it should be regulated. The industry fears overreach.
By Darius Tahir -
FDA’s Plan to Ban Hair Relaxer Chemical Called Too Little, Too Late
The FDA’s recent notice that it would move to ban formaldehyde in hair-straightening products comes more than a decade after researchers raised alarms about health risks. Scientists say a ban would still leave many dangerous chemicals in hair straighteners.
By Ronnie Cohen -
Ketamine Therapy for Mental Health a ‘Wild West’ for Doctors and Patients
Ketamine, approved by the FDA as an anesthetic in 1970, is emerging as a major alternative mental health treatment, and there are now more than 500 ketamine clinics around the country. But with little regulation and widely varying treatment protocols, it’s a medical "wild West."
By Dawn Megli -
Journalists Track Medical Device Malfunctions, Opioid Settlement Payments, and Abortion Bans
KFF Health News and California Healthline staffers made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
Patients With Narcolepsy Face a Dual Nightmare of Medication Shortages and Stigma
It's been more than a year since the FDA declared a national shortage of Adderall, and it’s affecting more than just patients with ADHD. Those with narcolepsy, a much rarer condition, are often treated with the same medication. Without it, they're often unable to drive or function as usual.
-
KFF Health News-CBS News Investigation
‘AGGA’ Inventor Testifies His Dental Device Was Not Meant for TMJ or Sleep Apnea
The FDA and Department of Justice are investigating the Anterior Growth Guidance Appliance, or “AGGA.” TMJ and sleep apnea patients have filed lawsuits alleging the device harmed them. Its inventor now says the AGGA was never meant for these ailments.
-
Deep Flaws in FDA Oversight of Medical Devices, and Patient Harm, Exposed in Lawsuits and Records
Thousands of medical devices are sold, and even implanted, with no safety tests.
By Fred Schulte and Holly K. Hacker -
Patients Facing Death Are Opting for a Lifesaving Heart Device — But at What Risk?
The HeartMate 3 is considered the safest mechanical heart pump of its kind, but a federal database contains more than 4,500 reports in which the medical device may have caused or contributed to a patient’s death.
By Daniel Chang and Holly K. Hacker -
Mysterious Morel Mushrooms at Center of Food Poisoning Outbreak
Federal officials issued their first guidelines on preparing morel mushrooms after a deadly food poisoning outbreak in Montana, noting the toxins in the delicacy aren’t fully understood.
By Keely Larson Democrats See Opportunity in GOP Threats to Repeal Health Law
Episode 325Sensing that Republicans are walking into a political minefield by threatening once again to repeal the Affordable Care Act, the Biden administration is looking to capitalize by rolling out a series of initiatives aimed at high drug prices and other consequences of “corporate greed in health care.” Meanwhile, the Supreme Court hears a case that could determine when and how much victims of the opioid crisis can collect from Purdue Pharma, the drug company that lied about how addictive its drug, OxyContin, really was. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Rachana Pradhan of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann of KFF Health News’ sister podcast, “An Arm and a Leg,” about his investigation into hospitals suing their patients over unpaid bills.
Trump Puts Obamacare Repeal Back on Agenda
Episode 324Although Republicans have never united behind a replacement for the Affordable Care Act, 2024 GOP presidential front-runner Donald Trump said this week he wants to put the issue back on the national agenda. That delights Democrats, who have won at least two elections partly by defending the now-popular health law. Meanwhile, the Texas Supreme Court takes up a case brought by women who say their pregnancy complications further endangered their health due to the vagueness of Texas’ near-total ban on abortions. Joanne Kenen of Johns Hopkins University and Politico Magazine, Sarah Karlin-Smith of the Pink Sheet, and Victoria Knight of Axios News join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Rachana Pradhan, who reported and wrote the latest “Bill of the Month” feature.
-
Is Novavax, the Latecomer Covid Vaccine, Worth the Wait?
People with special medical considerations are hoping the Novavax shot will bring fewer headaches, fevers, and less fatigue than have been reported by those taking mRNA vaccines.
By Amy Maxmen -
Doubts Abound About a New Alzheimer’s Blood Test
Quest Diagnostics is selling a blood test online to consumers. But results may not be reliable or easy to interpret. And it isn’t covered by insurance.
-
California Moves Ahead of the FDA in Banning Common Candy Additives
The legislation bans the use of four additives that are already prohibited in many other countries but remain in popular U.S. foods. Advocates say states need to act because the FDA has done little.
-
PrEP, a Key HIV Prevention Tool, Isn’t Reaching Black Women
New HIV infections occur disproportionately among Black women, but exclusionary marketing, fewer treatment options, and provider wariness have limited uptake of preexposure prophylaxis, or PrEP, drugs, which reduce the risk of contracting the virus.